2.6.16. Tests for extraneous agents in viral vaccines for human  
2.6.11. Depressor substances ................................................... 200 
2.5.6. Saponification value ....................................................... 169 
2.5.40. Methyl, ethyl and isopropyl toluenesulfonate in active 
2.5.38. Methyl, ethyl and isopropyl methanesulfonate in active 
substances .............................................................................. 185 
2.5.39. Methanesulfonyl chloride in methanesulfonic 
acid ......................................................................................... 184 
2.5.4. Iodine value ..................................................................... 168 
2.5.40. Methyl, ethyl and isopropyl toluenesulfonate in active 
substances .............................................................................. 186 
2.5.5. Peroxide value ................................................................. 168 
2.5.6. Saponification value ....................................................... 169 
2.5.7. Unsaifiable matter .......................................................... 169 
2.5.8. Determination of primary aromatic amino- 
nitrogen ................................................................................... 169 
2.5.9. Determination of nitrogen by sulfuric acid 
digestion .................................................................................... 170 
2.6. Biological tests .................................................................... 191 
2.6.1. Sterility ........................................................................... 191 
2.6.10. Histamine ...................................................................... 200 
2.6.11. Depressor substances ................................................... 200 
2.6.12. Microbiological examination of non-sterile products: 
microbial enumeration tests .................................................... 201 
2.6.13. Microbiological examination of non-sterile products: 
test for specified micro-organisms ........................................ 205 
2.6.14. Bacterial endotoxins ....................................................... 209 
2.6.15. Prekallikrein activator .................................................... 213 
2.6.16. Tests for extraneous agents in viral vaccines for human 
use......................................................................................... 10.2-4579 
2.7.17. Test for anticomplementary activity of 
immunoglobulin .................................................................... 216 
2.6.18. Test for neurovirulence of live virus vaccines .......... 218 
2.6.2. Mycobacteria .................................................................. 194 
2.6.20. Anti-A and anti-B haemagglutinins ...................... 218 
2.6.21. Nucleic acid amplification techniques .................. 219 
2.6.22. Activated coagulation factors ................................. 224 
2.6.23. 1,8-Diiodotyrosine in human immunoglobulin ....... 230 
2.6.24. Microbiological examination of cell-based 
preparations ............................................................................ 231 
2.6.25. Monocyte-activation test .............................................. 233 
2.6.31. Microbiological examination of herbal medicinal 
products for oral use and extracts used in their 
preparation .............................................................................. 239 
2.6.33. Residual pertussis toxin ............................................... 241 
2.6.34. Host-cell protein assays .............................................. 244 
2.6.35. Quantification and characterisation of residual 
host-cell DNA ......................................................................... 248 
2.6.36. Microbiological examination of live biotherapeutic 
products: tests for enumeration of microbial 
contaminants ......................................................................... 250 
2.6.37. Principles for the detection of extraneous viruses 
in immunological veterinary medicinal products using culture 
methods .................................................................................... 10.2-4581 
2.6.38. Microbiological examination of live biotherapeutic 
products: tests for specified micro-organisms .................. 255 
2.6.39. Mycoplasmas .................................................................. 194 
2.6.40. Pyrogens ........................................................................ 199 
2.7. Biocidal activity .................................................................... 199 
2.7.1. Immuonochemical methods ............................................ 261 
2.7.10. Assay of human coagulation factor VII .................. 280 
2.7.11. Assay of human coagulation factor IX .................... 281 
2.7.12. Assay of heparin in coagulation factors .................... 281 
2.7.13. Assay of human anti-D immunoglobulin ............. 282 
2.7.14. Assay of hepatitis A vaccine ....................................... 284 
2.7.15. Assay of hepatitis B vaccine (rDNA) ....................... 285 
2.7.16. Assay of pertussis vaccine ........................................... 286 
2.7.17. Assay of human antithrombin III ........................... 288 
2.7.18. Assay of human coagulation factor II ....................... 288 
2.7.19. Assay of human coagulation factor X ....................... 289 
2.7.2. Microbiological assay of antibiotics ......................... 262 
2.7.20. In vivo assay of poliomylitis vaccine (inactivated) .. 289 
2.7.21. Assay of human von Willebrand factor .................... 290 
2.7.22. Assay of human coagulation factor XI ...................... 291 
2.7.23. Numeration of CD34/CD45+ cells in haematopoietic 
products ................................................................................. 292 
2.7.24. Flow cytometry ............................................................ 293 
2.7.25. Assay of human plasmin inhibitor ............................ 295 
2.7.27. Floculation value (LF) of diphertheria and tetanus toxins 
and toxoids (Ramon assay)................................................... 295 
2.7.28. Colony-forming cell assay for human 
haematopoietic progenitor cells ........................................... 296 
2.7.29. Nucleated cell count and viability ............................ 297 
2.7.30. Assay of human protein C ............................................. 299 
2.7.31. Assay of human protein S .......................................... 300 
2.7.32. Assay of human α-1-proteinase inhibitor ............... 300 
2.7.34. Assay of human C1-esterase inhibitor ..................... 301 
2.7.35. Immunonephelometry for vaccine component 
assay ......................................................................................... 301 
2.7.4. Assay of human coagulation factor VIII .................... 268 
2.7.5. Assay of heparin ............................................................. 269 
2.7.6. Assay of diphertheria vaccine (adsorbed) .................. 269 
2.7.7. Assay of pertussis vaccine (whole cell) ....................... 274 
2.7.8. Assay of tetanus vaccine (adsorbed) ......................... 275 
2.7.9. Assay of tetanus vaccine .............................................. 276 
2.7.10. Assay of pertussis vaccine .......................................... 277 
2.8.4. Methods in pharmacognosy ........................................ 295 
2.8.5. Ash insoluble in hydrochloric acid ............................. 305 
2.8.6. Solubility in alcohol of essential oils ......................... 306 
2.8.11. Assay of 1,8-cineole in essential oils ....................... 307 
2.8.12. Essential oils in herbal drugs ................................. 307 
2.8.13. Pesticide residues ......................................................... 308 
2.8.14. Tannins in herbal drugs .............................................. 310 
2.8.15. Bitterness value ......................................................... 311 
2.8.16. Dry residue of extracts ............................................... 311 
2.8.17. Loss on drying of extracts ........................................... 311 
2.8.18. Determination of aflatoxin B1 in herbal drugs ......... 311 
2.8.2. Foreign matter ............................................................... 305 
2.8.20. Herbal drugs: sampling and sample preparation ..... 313 
2.8.21. Test for aristolochic acids in herbal drugs ............... 314 
2.8.22. Determination of ochratoxin A in herbal 
drugs ......................................................................................... 316 
2.8.23. Microscopic examination of herbal drugs .............. 317 
2.8.24. Foam index ................................................................. 317 
2.8.25. High-performance thin-layer chromatography of 
herbal drugs and herbal drug preparations .................... 318 
2.8.26. Water in essential oils .................................................. 306 
2.8.27. Water in essential oils .................................................. 306 
2.8.6. Foreign esters in essential oils ..................................... 306 
2.8.7. Fatty oils and resinified essential oils in essential 
oils .......................................................................................... 306 
2.8.8. Odour and taste of essential oils ................................. 306 
2.8.9. Residue on evaporation of essential oils .................. 306 
2.8.10. Pharmaceutical technical procedures ....................... 323 
2.8.11. Test for methanol and 2-propanol ......................... 323 
2.8.12. Disintegration of tablets and capsules ................. 323 
2.8.13. Sieve test ................................................................. 343 
2.8.14. Specific surface area by air permeability ............. 343 
2.8.15. Flowability ................................................................. 346 
2.8.16. Flowability ................................................................. 346 
2.8.17. Test for extractable volume of parenteral 
preparations ............................................................................ 347 
2.8.18. Preparations for inhalation: aerodynamic assessment 
of fine particles .................................................................. 347 
2.8.19. Particulate contamination: sub-visible particles..... 360 
2.8.20. Particulate contamination: visible particles ......... 362 
2.8.21. Disintegration of suppositories and pessaries ....... 325
Avian paramyxovirus 1 (Newcastle disease) vaccine
Avian infectious laryngotracheitis vaccine (live)............
Avian infectious encephalomyelitis vaccine (live).........
Avian infectious bursal disease vaccine (live)............
Avian infectious bursal disease vaccine (inactivated).......
Aujeszky's disease vaccine (live) for pigs for parenteral
Aurothiomalate, sodium........................................................3804
Atracurium besilate................................................................1894
Atractylodes rhizome, largehead..........................................1328
Atovaquone..............................................................................1892
Atorvastatin calcium trihydrate............................................1890
Atomic emission spectrometry, inductively coupled plasma-
Atenolol................................................................................94
Assay of poliomyelitis vaccine (inactivated),
Assay of pertussis vaccine (whole cell) (2.7.7.).....................274
Assay of pertussis vaccine (acellular) (2.7.16.)......................286
Assay of human plasmin inhibitor (2.7.25.)..........................295
Assay of human coagulation factor X (2.7.19.).....................289
Assay of human coagulation factor IX (2.7.11.)...................281
Assay of human antithrombin III (2.7.17.)............................288
Assay of human anti-D immunoglobulin (2.7.13.)..............282
Assay of human α-1-proteinase inhibitor (2.7.32.)..............300
Assay of heparin in coagulation factors (2.7.12.).................281
Assay of diphtheria vaccine (adsorbed) (2.7.6.)....................269
Aspartic acid............................................................................1883
Aspartame................................................................................1881
Atazanavir sulfate..........................................................
Assay of tetanus vaccine (adsorbed) (2.7.8.).........................275
Ash, total (2.4.16.)....................................................................143
Ash insoluble in hydrochloric acid (2.8.1.)...........................305
Ascorbyl palmitate..................................................................1879
Ascorbic acid...........................................................................1877
Ascorbate, sodium..................................................................3802
Ascorbate, calcium.................................................................2045
Atorvastatin calcium trihydrate............................................1890
Atomic emission spectrometry, inductively coupled plasma-
Atenolol..............................................................................
<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>647</td>
</tr>
<tr>
<td>3935</td>
</tr>
<tr>
<td>1344</td>
</tr>
<tr>
<td>1442</td>
</tr>
<tr>
<td>1343</td>
</tr>
<tr>
<td>1977</td>
</tr>
<tr>
<td>1343</td>
</tr>
<tr>
<td>1344</td>
</tr>
<tr>
<td>261</td>
</tr>
<tr>
<td>685</td>
</tr>
<tr>
<td>622</td>
</tr>
<tr>
<td>647</td>
</tr>
<tr>
<td>191</td>
</tr>
<tr>
<td>250</td>
</tr>
<tr>
<td>255</td>
</tr>
<tr>
<td>1979</td>
</tr>
<tr>
<td>2953</td>
</tr>
<tr>
<td>2953</td>
</tr>
<tr>
<td>1345</td>
</tr>
<tr>
<td>1982</td>
</tr>
<tr>
<td>1983</td>
</tr>
<tr>
<td>1984</td>
</tr>
<tr>
<td>1986</td>
</tr>
<tr>
<td>1986</td>
</tr>
<tr>
<td>1347</td>
</tr>
<tr>
<td>1433</td>
</tr>
<tr>
<td>1348</td>
</tr>
<tr>
<td>1350</td>
</tr>
<tr>
<td>1344</td>
</tr>
<tr>
<td>1352</td>
</tr>
<tr>
<td>1353</td>
</tr>
<tr>
<td>1550</td>
</tr>
<tr>
<td>1355</td>
</tr>
<tr>
<td>1358</td>
</tr>
<tr>
<td>1359</td>
</tr>
<tr>
<td>1989</td>
</tr>
<tr>
<td>465</td>
</tr>
<tr>
<td>465</td>
</tr>
<tr>
<td>473</td>
</tr>
<tr>
<td>469</td>
</tr>
<tr>
<td>1856</td>
</tr>
<tr>
<td>1360</td>
</tr>
<tr>
<td>1361</td>
</tr>
<tr>
<td>1363</td>
</tr>
<tr>
<td>1992</td>
</tr>
<tr>
<td>1992</td>
</tr>
<tr>
<td>1070</td>
</tr>
<tr>
<td>1993</td>
</tr>
<tr>
<td>1919</td>
</tr>
<tr>
<td>1927</td>
</tr>
<tr>
<td>2007</td>
</tr>
<tr>
<td>707</td>
</tr>
<tr>
<td>1076</td>
</tr>
<tr>
<td>922</td>
</tr>
<tr>
<td>1364</td>
</tr>
<tr>
<td>2009</td>
</tr>
<tr>
<td>2011</td>
</tr>
<tr>
<td>602</td>
</tr>
<tr>
<td>384</td>
</tr>
<tr>
<td>2014</td>
</tr>
<tr>
<td>2015</td>
</tr>
<tr>
<td>1365</td>
</tr>
<tr>
<td>2017</td>
</tr>
<tr>
<td>2019</td>
</tr>
<tr>
<td>102.4625</td>
</tr>
<tr>
<td>2031</td>
</tr>
<tr>
<td>907</td>
</tr>
<tr>
<td>1707</td>
</tr>
<tr>
<td>1707</td>
</tr>
<tr>
<td>2032</td>
</tr>
<tr>
<td>Index</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis (acellular, component) and hepatitis B (rDNA) vaccine (adsorbed)</td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed)</td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)</td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)</td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)</td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis (whole cell) and poliomyelitis (inactivated) vaccine (adsorbed)</td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis (whole cell) and poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)</td>
</tr>
</tbody>
</table>

**Index**

- **Diphtheria, tetanus, pertussis (acellular, component) and hepatitis B (rDNA) vaccine (adsorbed)**
- **Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed)**
- **Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)**
- **Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)**
- **Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)**
- **Diphtheria, tetanus, pertussis (whole cell) and poliomyelitis (inactivated) vaccine (adsorbed)**
- **Diphtheria, tetanus, pertussis (whole cell) and poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)**

**See the information section on general monographs (cover pages)**
Eyepreparations, semi-solid ......................................................... 910

F

F₀, concept to steam sterilisation of aqueous preparations, application of (5.1.5) ................................................................. 628

Factor II, human coagulation .......................................................... 268

Factor IX, human coagulation .......................................................... 2846

Factor IX, human coagulation, assay of (2.7.11) .................................. 281

Factor IX (rDNA) concentrated solution, human coagulation ................................................................. 2848

Factor IX (rDNA) powder for solution for injection, human coagulation ................................................................. 2853

Factor VII, human coagulation .......................................................... 2838

Factor VII, human coagulation, assay of (2.7.10) .................................. 280

Factor VIIa (rDNA) concentrated solution, human coagulation ................................................................. 2840

Factor VIII, human coagulation .......................................................... 2844

Factor VIII, human coagulation, assay of (2.7.4) ........................................ 286

Factor VIII (rDNA), human coagulation ........................................... 2845

Factor X, human coagulation, assay of (2.7.19) ........................................ 289

Factor XI, human coagulation .......................................................... 2855

Factor XI, human coagulation, assay of (2.7.22) .................................. 291

Falling ball and automatic rolling ball viscometer methods (2.2.49) ................................................................. 94

Famotidine ............................................................................... 2609

Fat, hard .................................................................................... 2811

Fat, hard with additives .................................................................. 2812

Fatty acids, composition by gas chromatography (2.4.22) ........... 147

Fatty acids in oils rich in omega-3 acids, composition of (2.4.29) ................................................................. 161

Fatty oils, alkaline impurities in (2.4.19) ........................................... 144

Fatty oils and refined essential oils in essential oils (2.8.7) ....................... 306

Fatty oils, foreign oils in, by thin-layer chromatography (2.4.21) ........... 147

Fatty oils, identification by thin-layer chromatography (2.3.2) ............... 132

Fatty oils, sterols in (2.4.23) ............................................................ 150

Fatty oils, vegetable ..................................................................... 901

Fc function of immunoglobulin, test for (2.7.9) ......................... 279

Febanest for veterinary use ................................................................ 2610

Felbinac .................................................................................... 2611

Feline calcivirus vaccine (inactivated) .................................................. 2580

Feline calcivirus vaccine (live) ......................................................... 10.2.4650

Feline chlamydiosis vaccine (inactivated) ............................................ 10.2.4650

Feline infectious enteritis (feline panleucopenia) vaccine (inactivated) ................................................................. 10.2.4650

Feline infectious enteritis (feline panleucopenia) vaccine (live) ................................................................. 10.2.4650

Feline leukemia vaccine (inactivated) .................................................. 1112

Feline panleucopenia vaccine (inactivated) ............................................ 10.2.4650

Feline panleucopenia vaccine (live) ....................................................... 10.2.4650

Feline viral rhinotracheitis vaccine (inactivated) ................................... 1113

Feline viral rhinotracheitis vaccine (live) .................................................. 10.2.4652

Felodipine .................................................................................. 2612

Felprofesin .................................................................................. 2614

Fenbendazole for veterinary use ....................................................... 2615

Fenbucfen .................................................................................. 2616

Fennel, bitter.................................................................................. 1433

Fennel, sweet ............................................................................. 1434

Fenobistrate .................................................................................. 2617

Fenoterol hydrobromide .................................................................. 2618

Fentanyl ....................................................................................... 2619

Fentanyl citrate ............................................................................ 2621

Fenticonazole nitrate ....................................................................... 2622

Fenugreek .................................................................................... 1435

Fermentation, products of .................................................................. 882

Ferric chloride hexahydrate ............................................................ 2624

Ferric fumarate ............................................................................... 2624

Ferrous fumarate ............................................................................. 2624

Ferrous gluconate ............................................................................ 2625

Ferrous sulfate, dried ....................................................................... 2626

Ethanol, anhydrous ........................................................................ 2575

Ethanol content (2.9.10) .................................................................. 339

Ether .............................................................................................. 2577

Ether, anesthetic ............................................................................. 2579

Ethinylestradiol ............................................................................ 2578

Ethionamide .................................................................................... 2580

Ethosuximide .................................................................................... 2581

Ethoxyated substances, ethylene glycol and diethylene glycol in (2.4.30) ................................................................................................. 163

Ethyl acetate .................................................................................... 2582

Ethyl acrylate - methacrylic acid copolymer (1:1) .................................... 3214

Ethyl acrylate - methacrylic acid copolymer (1:1) dispersion 30 per cent .......................................................................................... 3216

Ethyl oleate ...................................................................................... 2583

Ethyl parahydroxybenzoate ............................................................ 2583

Ethyl parahydroxybenzoate sodium .................................................. 3816

Ethylcellulose .................................................................................... 2585

Ethylene glycol and diethylene glycol in ethoxyrated substances (2.4.30) ................................................................................................. 163

Ethylene glycol monopalmitostearate ............................................ 2586

Ethylene glycol monostearate ............................................................ 2586

Ethylene oxide and dioxan (2.4.25) ..................................................... 157

Ethylennediamine ............................................................................ 2587

Ethylhexanoic acid, 2- (2.4.28) ............................................................ 160

Ethylmorphine hydrochloride ............................................................ 2587

Etidrate disodium ............................................................................. 2589

Etilefine hydrochloride ..................................................................... 2589

Etodolac ............................................................................................ 2591

Etopenamide .................................................................................... 2593

Etomidate .......................................................................................... 2595

Etoposide .......................................................................................... 2596

Eucalyptus leaf .................................................................................. 1428

Eucalyptus oil .................................................................................... 1429

Eucommia bark .................................................................................. 1430

Eugenol ............................................................................................. 2599

European goldenrod ....................................................................... 1460

European viper venom antiserum ...................................................... 1174

Evaluation of efficacy of veterinary vaccines and immunosera (5.2.7) ................................................................. 661

Evaluation of safety of each batch of immunosera for veterinary use (5.2.9) ................................................................. 673

Evaluation of safety of veterinary vaccines and immunosera (5.2.6) ................................................................. 658

Evening primrose oil, refined ............................................................. 2601

Everolimus ....................................................................................... 2601

Evodia fruit ........................................................................................ 1431

Eucalyptus oil, foreign oils in, by thin-layer chromatography (2.4.21) ................................................................. 147

Eye preparations, semi-solid ............................................................. 910

Eye lotions .......................................................................................... 910

Eye preparations ............................................................................. 909
Gases, nitrous oxide in (2.5.35.) ........................................ 182
Gases, oxygen in (2.5.27) .................................................. 176
Gases, water in (2.5.28) ..................................................... 176
Gastric acid, mixed .......................................................... 1151
Gas-gangrene antitoxin (noyvi) ......................................... 1171
Gas-gangrene antitoxin (perfringens) .................................. 1171
Gas-gangrene antitoxin (septicum) .................................... 1172
Gastrodia rhizome ............................................................ 1447
Gastro-resistant capsules ................................................. 907
Gastro-resistant granules .................................................. 913
Gastro-resistant tablets .................................................... 728
Geldin ................................................................. 2737
Gelatin ........................................................................ 2738
Gels ............................................................................. 936
Gels for injections ......................................................... 925
Gemcitabine hydrochloride .............................................. 2739
Gemfibrozil ...................................................................... 2740
Gene transfer medicinal products for human use (5.14).... 779
General notices (1) .......................................................... 3
General texts on biological products (5.2) ......................... 647
General texts on microbiology (5.1) ................................. 619
Genetically modified cells ................................................ 779
Gentamicin sulfate .......................................................... 2742
Gentian root ................................................................. 1448
Gentian tincture .............................................................. 1449
Gelsemine ................................................................. 2744
Ginger ........................................................................ 1450
Gingival solutions ........................................................... 921
Ginkgo dry extract, refined and quantified ......................... 1451
Ginkgo leaf ..................................................................... 1454
Ginseng ......................................................................... 1455
Ginseng dry extract ........................................................ 1455
Glass containers for pharmaceutical use (3.2.1) ............... 453
Glubenclamide ............................................................... 2746
Gliclazide ....................................................................... 2747
Glimepiride ..................................................................... 2749
Glipizide ......................................................................... 2751
Glossary (dosage forms) .................................................. 905
Glucagon, human ............................................................ 2753
Glucocorticosteroids, calcium .......................................... 2051
Glucosamine hydrochloride ............................................ 2754
Glucosamine sulfate potassium chloride ......................... 2755
Glucosamine sulfate sodium chloride ............................... 2757
Glucose ........................................................................... 2758
Glucose, liquid ............................................................... 2759
Glucose, liquid, spray-dried .............................................. 2760
Glucose monohydrate ..................................................... 2761
Glutamic acid .................................................................. 2762
Glutathione ...................................................................... 2763
Glycan analysis of glycoproteins (2.2.59) ......................... 109
Glycerol .......................................................................... 2765
Glycerol (85 per cent) ..................................................... 2766
Glycerol dibehenate ........................................................ 2767
Glycerol distearate .......................................................... 2768
Glycerol formal ............................................................... 2769
Glycerol monacrylate ...................................................... 2770
Glycerol monacrylopcrate ................................................. 2771
Glycerol monolinoate ....................................................... 2772
Glycerol mono-oleate ....................................................... 2773
Glycerol monostearate 40-55 ........................................... 2774
Glycerol tristearate ......................................................... 4083
Glyceryl trinitrate solution ................................................. 2775
Glycine ............................................................................ 2777
Glycoproteins, glycan analysis of (2.2.59) ....................... 109
Glycopyrrotonium bromide ............................................. 2779
Glycryrrhizate ammonium ................................................. 1833
Goldenrod ................................................................. 1458
Goldenrod, European ..................................................... 1460
Gonadotrophin, rhinose ................................................... 2781
Gonadotrophin, chorionic ................................................ 2782
Gonadotrophin, equine serum, for veterinary use ............. 2783
Goserelin ................................................................. 2783

H
Haemagglutinins, anti-A and anti-B (2.6.20) ......................... 218
Haematopoietic products, numbering of CD34/CD45+ cells (2.7.23) .......................................................... 292
Haematopoietic progenitor cells, human, colony-forming cell assay for (2.7.28) .............................................. 296
Haematopoietic stem cells, human .................................... 2857
Haemodialysis, concentrated solutions for ....................... 2798
Haemodialysis solutions, concentrated, water for diluting .......................................................... 2797
Haemodialysis, solutions for ........................................... 2798
Haemofiltration and haemodiafiltration, concentrated solutions for .......................................................... 2801
Haemofiltration and haemodiafiltration, solutions for ........ 2803
Haemophilus type b and meningococcal group C conjugate vaccine .......................................................... 979
Haemophilus type b (conjugate), diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed) ...... 961
Haemophilus type b (conjugate), diphtheria, tetanus, pertussis (acellular, component) and poliomylitis (inactivated) vaccine (adsorbed) ......................................................... 970
Haemophilus type b conjugate, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA) and polimylitis (inactivated) vaccine (adsorbed) ......................................................... 968
Haemophilus type b (conjugate), diphtheria, tetanus, pertussis (whole cell) and poliomylitis (inactivated) vaccine (adsorbed) ......................................................... 974
Haemophilus type b conjugate vaccine ................................ 980
Haemorrhagic disease vaccine (inactivated), rabbit 10.2.4665
Haloantirine hydrochloride ................................................ 2805
Haloperidol ................................................................. 2806
Haloperidol decanoate ..................................................... 2808
Halothane ...................................................................... 2809
Hamamelis bark ............................................................ 2808
Hamamelis leaf .............................................................. 1469
Hamamelis capsules ....................................................... 910
Hard fat ................................................................. 2811
Hard fat with additives .................................................. 2812
Har paraffin ............................................................... 3483
Harmonisation, pharmacopoeial (5.8) .............................. 755
Hawthorn berries .......................................................... 10.1.4357
Hawthorn leaf and flower ................................................... 1471
Hawthorn leaf and flower dry extract ................................. 1471
Hawthorn leaf and flower liquid extract, quantified .......... 1473
HCP assays (2.6.34) ........................................................ 244

See the information section on general monographs (cover pages)
<table>
<thead>
<tr>
<th>Ingredient</th>
<th>10.2</th>
<th>4.389</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrogenated vegetable oils, nickel in (2.4.31.)</td>
<td>163</td>
<td></td>
</tr>
<tr>
<td>Hydrogenated wool fat</td>
<td>4215</td>
<td></td>
</tr>
<tr>
<td>Hydromorphone hydrochloride</td>
<td>2890</td>
<td></td>
</tr>
<tr>
<td>Hydrophobic colloidal silica</td>
<td>2859</td>
<td></td>
</tr>
<tr>
<td>Hydrous wool fat</td>
<td>4216</td>
<td></td>
</tr>
<tr>
<td>Hydroxocobalamin acetate</td>
<td>2892</td>
<td></td>
</tr>
<tr>
<td>Hydroxocobalamin chloride</td>
<td>2893</td>
<td></td>
</tr>
<tr>
<td>Hydroxocobalamin sulfate</td>
<td>2894</td>
<td></td>
</tr>
<tr>
<td>Hydroxy carbamide</td>
<td>2895</td>
<td></td>
</tr>
<tr>
<td>Hydroxychlороquine sulfate</td>
<td>2896</td>
<td></td>
</tr>
<tr>
<td>Hydroxyethyl salicylate</td>
<td>2897</td>
<td></td>
</tr>
<tr>
<td>Hydroxyethyl stearates</td>
<td>3892</td>
<td></td>
</tr>
<tr>
<td>Hydroxyethylcellulose</td>
<td>2898</td>
<td></td>
</tr>
<tr>
<td>Hydroxyethyl-methylcellulose</td>
<td>3237</td>
<td></td>
</tr>
<tr>
<td>Hydroxyl value (2.5.3.)</td>
<td>167</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropyl starch</td>
<td>3888</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropyl starch, pregelatinised</td>
<td>3890</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropylbetadex</td>
<td>2901</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td>2903</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropylcellulose, low-substituted</td>
<td>2904</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropylmethylcellulose</td>
<td>2914</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropylmethylcellulose phthalate</td>
<td>2916</td>
<td></td>
</tr>
<tr>
<td>Hydroxyzine hydrochloride</td>
<td>2906</td>
<td></td>
</tr>
<tr>
<td>Hymecromone</td>
<td>2907</td>
<td></td>
</tr>
<tr>
<td>Hymenoptera venoms for allergen products</td>
<td>2908</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine</td>
<td>2909</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine butylbromide</td>
<td>2910</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine hydrobromide</td>
<td>2911</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine sulfate</td>
<td>2913</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine sulfates</td>
<td>2914</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine sulfates for homoeopathic preparations</td>
<td>1717</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine sulfates for intravenous preparations</td>
<td>1631</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine sulfates for interstitial fluid preparations</td>
<td>1718</td>
<td></td>
</tr>
<tr>
<td>Hypromellose</td>
<td>2914</td>
<td></td>
</tr>
<tr>
<td>Hypromellose phthalate</td>
<td>2916</td>
<td></td>
</tr>
<tr>
<td>Hydroxocobalamin acetate</td>
<td>2892</td>
<td></td>
</tr>
<tr>
<td>Hydroxocobalamin chloride</td>
<td>2893</td>
<td></td>
</tr>
<tr>
<td>Hydroxocobalamin sulfate</td>
<td>2894</td>
<td></td>
</tr>
<tr>
<td>Hydroxy carbamide</td>
<td>2895</td>
<td></td>
</tr>
<tr>
<td>Hydroxychlороquine sulfate</td>
<td>2896</td>
<td></td>
</tr>
<tr>
<td>Hydroxyethyl salicylate</td>
<td>2897</td>
<td></td>
</tr>
<tr>
<td>Hydroxyethyl stearates</td>
<td>3892</td>
<td></td>
</tr>
<tr>
<td>Hydroxyethylcellulose</td>
<td>2898</td>
<td></td>
</tr>
<tr>
<td>Hydroxyethyl-methylcellulose</td>
<td>3237</td>
<td></td>
</tr>
<tr>
<td>Hydroxyl value (2.5.3.)</td>
<td>167</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropyl starch</td>
<td>3888</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropyl starch, pregelatinised</td>
<td>3890</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropylbetadex</td>
<td>2901</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td>2903</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropylcellulose, low-substituted</td>
<td>2904</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropylmethylcellulose</td>
<td>2914</td>
<td></td>
</tr>
<tr>
<td>Hydroxypropylmethylcellulose phthalate</td>
<td>2916</td>
<td></td>
</tr>
<tr>
<td>Hydroxyzine hydrochloride</td>
<td>2906</td>
<td></td>
</tr>
<tr>
<td>Hymecromone</td>
<td>2907</td>
<td></td>
</tr>
<tr>
<td>Hymenoptera venoms for allergen products</td>
<td>2908</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine</td>
<td>2909</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine butylbromide</td>
<td>2910</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine hydrobromide</td>
<td>2911</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine sulfates</td>
<td>2913</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine sulfates for homoeopathic preparations</td>
<td>1717</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine sulfates for intravenous preparations</td>
<td>1631</td>
<td></td>
</tr>
<tr>
<td>Hydroxyuridine sulfates for interstitial fluid preparations</td>
<td>1718</td>
<td></td>
</tr>
<tr>
<td>Hypromellose</td>
<td>2914</td>
<td></td>
</tr>
<tr>
<td>Hypromellose phthalate</td>
<td>2916</td>
<td></td>
</tr>
</tbody>
</table>

See the information section on general monographs (cover pages)
Index
Index

Nifedipine ................................................................. 3360
Niflumic acid ............................................................ 3362
Nifuroxazide .............................................................. 3363
Nifuroxime ............................................................... 3373
Nilotinib hydrochloride monohydrate ......................... 3365
Nilitamide ............................................................... 3367
Nimesulide .............................................................. 3368
Nimodipine .............................................................. 3369
Nitrazepam .............................................................. 3371
Nitrendipine ............................................................ 3372
Nitric acid ............................................................... 3373
Nitros oxide ............................................................. 3374
Nitrofurantoin .......................................................... 3375
Nitrogen ................................................................. 3376
Nitrogen determination by sulfuric acid digestion (2.5.9.).. 170
Nitrogen determination, primary aromatic amino (2.5.8.).. 169
Nitrogen, low-oxygen .................................................. 3377
Nitrogen monoxide and nitrogen dioxide in gases (2.5.6.) (2.5.26.) ......................................................... 176
Nitroprusside, sodium ................................................. 3832
Nitrous oxide ........................................................... 3377
Nitrous oxide in gases (2.5.35.) ..................................... 182
Nizatidine ............................................................... 3379
N-Methylpyrrolidone .................................................. 3246
N,N-Dimethylacetamide ............................................. 3247
NMR spectrometry .................................................... 58
NMR spectrometry, peptide identification by (2.2.64.)..... 118
N,N-Dimethylalanine (2.4.26.) ...................................... 158
Nomegestrol acetate ................................................... 101-4459
Nonoxinol 9 .............................................................. 3381
Non-sterile pharmaceutical preparations and substances for pharmaceutical use, microbiological quality of (5.1.4.).......... 627
Non-sterile products, micro-biological examination of (microbial enumeration tests) (2.6.12.) ................................. 201
Non-sterile products, micro-biological examination of (test for specified micro-organisms) (2.6.13.) ................................. 205
Noradrenaline hydrochloride ........................................ 3382
Noradrenaline tartrate .................................................. 3384
Norepinephrine hydrochloride ...................................... 3382
Norepinephrine tartrate .............................................. 3384
Norhistrone ............................................................. 3385
Norhistrone acetate .................................................... 3387
Norfluroxacin ........................................................... 3388
Norflurane .............................................................. 3390
Norgestimate ........................................................... 3396
Norgestrel ............................................................... 3397
Noreliz for intramuscular injection human ..................... 2860
Noreliz for intravenous administration human ................. 2862
Normal immunoglobulin for intravenous administration, human ................................................................. 2862
Normal immunoglobulin for subcutaneous administration, human ................................................................. 2864
Nortriptyline hydrochloride ......................................... 3397
Noscaphine ............................................................. 3399
Noscaphine hydrochloride hydrate ................................ 3400
Notoginseng root ....................................................... 1555
Nuclear magnetic resonance spectrometry (2.2.33.) ......... 58
Nuclear magnetic resonance spectrometry, peptide identification by (2.6.64.) ..................................................... 118
Nucleated cell count and viability (2.7.29.) ...................... 297
Nucleic acid amplification techniques (2.6.21.) .......... 219
Nucleic acids in polysaccharide vaccines (2.5.17.) ............ 172
Numeration of CD34/CD45+ cells in haematopoietic products (2.7.23.) ......................................................... 292
Nutmeg oil ............................................................... 1556
Nux-vomica for homoeopathic preparations .................... 1723
Nystatin ................................................................. 3401
O
O-Acetyl in polysaccharide vaccines (2.5.19.) ................. 173
Oak bark ............................................................... 1557
Octoxinol 10 ............................................................ 3405

Ocrotide ................................................................. 3405
Octyl galate ............................................................ 3407
Octylidocanole .......................................................... 3407
Octylparaben (2.3.4.) .................................................. 132
Odour and taste of essential oils (2.8.8.) ......................... 306
Oflloxacin ............................................................... 3408
Oils, essential .......................................................... 864
Oils, fatty, identification by thin-layer chromatography (2.3.2.) ................................................................. 132
Oils, fatty, vegetable .................................................. 901
Oils rich in omega-3 acids, composition of fatty acids in (2.4.29.) ................................................................. 161
Oils rich in omega-3 acids, total cholesterol in (2.4.32.) .. 163
Ointments ............................................................... 936
Olive acid ............................................................... 3411
Oleoresins .............................................................. 868
Oleoyl macroglycerides ............................................. 3411
Oleyl alcohol ............................................................ 3412
Olive leaf ............................................................... 1557
Olive leaf dry extract .................................................. 1559
Olive oil ................................................................. 3413
Olive oil, virgin ........................................................ 3414
Olmetsartan medoxomil ............................................. 3415
Olsalazine sodium .................................................... 3417
Omega-3 acids, composition of fatty acids in oils rich in (2.4.29.) ................................................................. 161
Omega-3 acids, fish oil rich in ......................................... 2639
Omega-3 acids, total cholesterol in oils rich in (2.4.32.) .. 163
Omega-3-acid ethyl esters 60 ........................................ 3419
Omega-3-acid ethyl esters 90 ........................................ 3421
Omega-3-acid triglycerides ........................................... 3423
Omeprazole ............................................................. 3425
Omeprazole magnesium ............................................. 3427
Omeprazole sodium ................................................... 3428
Ondansetron hydrochloride dihydrate ............................. 3430
Opalescence of liquids, clarity and degree of (2.2.1.) ... 21
Ophthalamic inserts .................................................... 910
Opium dry extract, standardised .................................... 1560
Opium, prepared ...................................................... 1561
Opium, raw ............................................................ 1562
Opium tincture, standardised ....................................... 1564
Optical microsopy (2.9.37.) ........................................ 390
Optical rotation (2.2.7.) .............................................. 26
Orbifloxacin for veterinary use ....................................... 3431
Orbifloxacin for veterinary use ....................................... 3433
Oregano ............................................................... 1565
Organ preservation, solutions for ................................ 3852
Oriental cashew for homoeopathic preparations ............... 1702
Oriental cashew stem ................................................ 1561
Orientvine stem ....................................................... 1567
Orotidine ............................................................... 3434
Orphenadrine citrate .................................................. 3434
Orphenadrine hydrochloride ........................................ 3436
Oseltamivir phosphate ............................................... 3437
Osmolality (2.2.35.) ................................................... 63
See the information section on general monographs (cover pages)
Ouabain .......................................................... 3439
Oxacillin sodium monohydrate ................................. 3440
Oxaliplatin .......................................................... 3442
Oxazepam ............................................................ 3445
Oxcarbazepine ...................................................... 3446
Oxeladin hydrogen citrate ........................................ 3448
Oxendazole for veterinary use ................................... 10.1-4663
Oxidising substances (2.5.30.) .................................. 177
Oxitropium bromide .............................................. 3450
Oxolinic acid ......................................................... 3451
Oxyhydrocortisone hydrochloride .............................. 3454
Oxybutynin hydrochloride ........................................ 3454
Oxycodeone hydrochloride ....................................... 3455
Oxygent (93 per cent) .............................................. 3457
Oxygen in gases (2.5.27.) ......................................... 176
Oxygen-flask method (2.5.10.) .................................. 170
Oxymetazoline hydrochloride .................................... 10.1-4664
Oxytetracycline dihydrate ........................................ 10.2-4678
Oxytetracycline hydrochloride ................................... 3462
Oxytocin ............................................................. 3464
Oxytocin concentrated solution .................................. 3465

P

Pacitaxel .......................................................... 3469
Pale coneflower root ............................................. 1568
Palmitic acid ........................................................ 3473
Pamidronate disodium pentahydrate .......................... 3474
Pancreas powder .................................................... 3474
Pancreatic necrosis vaccine (inactivated, oil-adjuvanted, 
injectable) for salmonids, infectious ................................ 1124
Pancuronium bromide ............................................ 3477
Panleucopenia vaccine (inactivated), feline ................. 1189
Panleucopenia vaccine (live), feline ............................ 10.2-4651
Pansy, wild (flowering aerial parts) ............................ 1668
Papaveraceae—sodium sesquihydrate ......................... 3478
Pantothenic acid, calcium ........................................ 2063
Papaverine hydrochloride ........................................ 3480
Paper chromatography (2.2.26.) ............................... 46
Papillomavirus vaccine (rDNA), human ...................... 989
Paraben, methyl .................................................... 3229
Paraben, propyl .................................................... 3660
Paraben, sodium ethyl ............................................ 3816
Paraben, sodium methyl ......................................... 3830
Paraben, sodium propyl .......................................... 3838
Paracetamol ......................................................... 3481
Paraffin, hard ....................................................... 3483
Paraffin, light liquid ............................................... 3483
Paraffin, liquid ...................................................... 3483
Paraffin, white soft ............................................... 3485
Paraffin, yellow soft ............................................... 3486
Parahydroxybenzoate, butyl ................................... 2025
Parahydroxybenzoate, ethyl .................................... 2583
Parahydroxybenzoate, methyl ................................... 3229
Parahydroxybenzoate, propyl ................................... 3660
Parahydroxybenzoate, sodium ethyl .......................... 3816
Parahydroxybenzoate, sodium methyl ....................... 3830
Parahydroxybenzoate, sodium propyl ....................... 3838
Parainfluenza virus vaccine (live), bovine ................. 10.2-4633
Parainfluenza virus vaccine (live), canine ................... 10.2-4640
Paraldehyde ........................................................ 3486
Paramyxovirus 1 (Newcastle disease) vaccine (inactivated), 
avian ............................................................... 10.2-4660
Paramyxovirus 1 (Newcastle disease) vaccine (live), 
avian ............................................................... 10.2-4661
Paramyxovirus 3 vaccine (inactivated) for turkeys, 
avian ............................................................... 10.2-4631
Parenteral preparations ........................................... 923
Parenteral preparations, test for extractable volume 
of (2.9.17.) .......................................................... 347
Parnaparin sodium ................................................ 3487
Paroxetine hydrochloride .......................................... 3490
Paroxetine hydrochloride hemihydrate ....................... 3490
Particle size analysis by laser light diffraction (2.9.31.) .. 373
Particles, fine, aerodynamic measurement of in preparations 
for inhalation (2.9.18.) ............................................ 347
Particle-size distribution estimation by analytical sieving 
(2.9.38.) ............................................................. 392
Particulate contamination: sub-visible particles (2.9.19.) .. 360
Particulate contamination: visible particles (2.9.20.) ....... 362
Parvovirus vaccine (inactivated), canine ....................... 1085
Parvovirus vaccine (inactivated), porcine ..................... 10.2-4663
Parvovirus vaccine (live), canine ................................ 10.2-4641
Passion flower ..................................................... 1570
Passion flower dry extract ....................................... 1571
Pastes .................................................................... 936
Pasturella vaccine (inactivated) for sheep ..................... 1138
Pastilles and lozenges ............................................. 922
Patches, cutaneous ............................................... 935
Patches, transdermal .............................................. 925
Patches, transdermal, dissolution test for (2.9.4.) .......... 333
Pea starch ............................................................ 3492
Pelargonium root .................................................... 1571
Penemetraxide disodium heptahydrate ......................... 3494
Penbutolol sulfate .................................................. 3497
Penetrometry, measurement of consistency by (2.9.9.) ...... 337
Penicillamine ........................................................ 3498
Penicillin G (benzathine) tetrahydrate ......................... 1951
Penicillin G potassium ............................................ 1953
Penicillin G (procaine) monohydrate ........................... 1955
Penicillin G sodium ............................................... 1957
Penicillin V .......................................................... 10.2-4683
Penicillin V (benzathine) tetrahydrate .......................... 3531
Penicillin V potassium ............................................. 10.2-4684
Penetaerythritol tetranitrate, diluted .......................... 3499
Pentamidine disosetionate ......................................... 3501
Pentazocine .......................................................... 3502
Pentazocine hydrochloride ........................................ 3502
Pentazocine lactate ............................................... 3503
Pentetate sodium calcium for radiopharmaceutical 
preparations ......................................................... 1223
Pentobarbital ......................................................... 3504
Pentobarbital sodium ............................................... 3505
Pentoxifylline ........................................................ 4461
Pentoxifylline hydrogen citrate .................................... 4461
Pentoxifylline pentahydrate ........................................ 3509
Peony root, red .................................................... 1572
Peony root, white .................................................. 1573
Pepper .................................................................... 1575
Pepper, long .......................................................... 1510
Peppermint leaf extract ............................................ 1577
Peppermint oil ....................................................... 1578
Peppermint oil ....................................................... 1579
Pepsin powder ....................................................... 3509
Peptide identification by nuclear magnetic resonance 
spectrometry (2.2.64.) ............................................ 118
Peptide mapping (2.2.55.) ......................................... 97
Peptides, synthetic, acetic acid in (2.5.34.) .................... 181
Perborate, hydrated sodium ...................................... 3833
Perfamol mesilate .................................................. 3511
Perindopril tert-butylamine ....................................... 10.1-4470
Peritoneal dialysis, solutions for ................................ 3515
Permethrin (25:75) .................................................. 3517
Peroxide value (2.9.17.) ............................................ 347
Peroxide value (2.9.18.) ............................................ 347
Perphenazine ........................................................ 3519
Persilvirus (acellulare, component), diphertheria and tetanus 
vaccine (adsorbed) ................................................ 955
Persilvirus (acellulare, component), diphertheria and tetanus 
vaccine (adsorbed, reduced antigen(s) content) ............ 956
Persilvirus (acellulare, component), diphertheria and haemophilus type b conjugate vaccine (adsorbed) .......... 961
Radiopharmaceutical preparations, medronic acid for .............................................................. 1219
Radiopharmaceutical preparations, pentate sodium calcium for ........................................ 1223
Radiopharmaceutical preparations, sodium lodophosphate dihydrate for .................................... 1234
Radiopharmaceutical preparations, sodium pyrophosphate dehydrate for .................................. 1241
Radiopharmaceutical preparations, tetra-O-acetyl-mannose trflate for ...................................... 1261
Radiopharmaceuticals, extemporary preparation of ...................................................................... 1266
Ratoloxine hydrochloride .............................................................................................................. 3699
Raltegravir chewable tablets ........................................................................................................... 3702
Raltegravir potassium ...................................................................................................................... 3701
Raltegravir tablets ............................................................................................................................ 3704
Raman spectroscopy (2.2.48) ............................................................................................................. 92
Ramipril ............................................................................................................................................... 3705
Raman assay, flotation value (LF) of diphtheria and tetanus toxins and toxoids (2.27.) ................................................. 295
Ranitidine hydrochloride .................................................................................................................. 10.2-4689
Rapseed oil, refined ......................................................................................................................... 3709
Raspberry leaf .................................................................................................................................. 10.1-4359
Raw materials of biological origin for the production of cell-based and gene therapy medicinal products (5.12.) ...................................................... 675
Reagents (4.) ....................................................................................................................................... 481
Reagents (4.1.) .................................................................................................................................... 3719
Reagents (4.1.1.) .................................................................................................................................. 10.1-4331
Reagents (4.1.1.1.) ................................................................................................................................. 10.2-4585
Reagents, standard solutions, buffer solutions (4.1) ..................................................................... 481
Recombinant DNA technology, products of ...................................................................................... 888
Recombinant vectors ........................................................................................................................... 779
Recommendations on dissolution testing (5.17.1) ......................................................................... 801
Recommendations on methods for dosage forms testing (5.17.) ....................................................... 801
Rectal capsules ................................................................................................................................. 934
Rectal foams ....................................................................................................................................... 935
Rectal preparations ............................................................................................................................. 933
Rectal preparations, semi-solid ......................................................................................................... 935
Rectal solutions and suspensions, powders and tablets for ............................................................. 933
Residual solvents, identification and control of ................................................................................ 306
Residual solvents, identification and control of ................................................................................ 241
Residual solvents (5.4.) ....................................................................................................................... 717
Reserpine ............................................................................................................................................. 3715
Residual pertussis toxin (2.6.33) ...................................................................................................... 241
Residual solvents (5.4.) ....................................................................................................................... 717
Residue on evaporation of essential oils (2.8.9) .............................................................................. 306
Residues, pesticide (2.8.13) .............................................................................................................. 308
Resistance to crushing of tablets (2.9.8) ......................................................................................... 337
Resorcinol ............................................................................................................................................ 3716
Respiratory syncytial virus vaccine (live), bovine ......................................................................... 10.2-4634
Retrograd root .................................................................................................................................... 1596
Rhatany root ....................................................................................................................................... 1597
Rhatany tincture ............................................................................................................................... 1598
Rhinotracehtis vaccine (inactivated), bovine, infectious ................................................................ 1120
Rhinotrachitis vaccine (inactivated), viral, feline .......................................................................... 1113
Rhinotrachitis vaccine (inactivated), viral, feline, infectious ............................................................ 1113
Rhinotrachitis vaccine (inactivated), viral, feline, infectious, turkey ................................................ 10.2-4668
Rhinotrachitis vaccine (live), bovine ............................................................................................... 10.2-4654
Rhinotrachitis vaccine (live), bovine, infectious, turkey ................................................................ 10.2-4668
Ribabor .............................................................................................................................................. 3717
Ribavirin ............................................................................................................................................. 3717
Riboflavin ............................................................................................................................................ 3718
Riboflavin sodium phosphate .......................................................................................................... 3720
Ribose in polysaccharide vaccines (2.5.31.) .................................................................................... 177

ribwort plantain ................................................................................................................................. 1599
rice starch ........................................................................................................................................ 3721
rifabutin .............................................................................................................................................. 3722
rifampicin ........................................................................................................................................... 3723
rifamycin sodium ............................................................................................................................... 3725
rifaximin ............................................................................................................................................. 3726
rilmenidene dihydrogen phosphate ................................................................................................. 3728
risendronate sodium 2.5-hydrate ................................................................................................. 3729
risperidone ......................................................................................................................................... 3730
ritonavir ............................................................................................................................................... 3732
sitagliptine .......................................................................................................................................... 3737
rivastigmine hydrogen tartrate ......................................................................................................... 3737
rizatRIPTAN benzoate .................................................................................................................... 3739
rocuronium bromide ....................................................................................................................... 3740
Rolling ball (automatic) and falling ball viscometer methods (2.2.49) ........................................ 94
Roman chamomile flower ................................................................................................................. 1384
ropinirole hydrochloride ................................................................................................................... 42
ropivacaine hydrochloride monohydrate ........................................................................................ 3744
roselle ................................................................................................................................................. 1600
rosemary leaf .................................................................................................................................... 1601
rosemary oil ....................................................................................................................................... 1603
rosuvastatin calcium ........................................................................................................................ 10.1-4484
rosuvastatin tablets ........................................................................................................................ 10.1-4487
Rotating viscometer method - viscosity (2.2.10) .............................................................................. 28
Rotavirus diarrhoea vaccine (inactivated), calf ................................................................................ 10.2-4636
Rotavirus vaccine (live, oral) .......................................................................................................... 1033
Rotigotine .......................................................................................................................................... 3748
Round ammonium fruit ...................................................................................................................... 1604
roxithromycin .................................................................................................................................. 3750
RR-α-Tocopherol ............................................................................................................................. 4058
RR-α-Tocopherol acetate ................................................................................................................... 4060
RR-α-Tocopherol hydrogen succinate ............................................................................................. 4064
Rubber closures for containers for aqueous parenteral preparations, for powders and for freeze-dried powders (3.2.9) ......................................................................................................................... 460
Rubella immunoglobulin, human ..................................................................................................... 2872
Rubella, measles and mumps vaccine (live) ..................................................................................... 1005
Rubella, measles, mumps and varicella vaccine (live) .................................................................... 1006
Rubella vaccine (live) ....................................................................................................................... 1035
Ruminant colibacillosis vaccine (inactivated), neonatal ................................................................ 1133
rupatadine fumarate ......................................................................................................................... 3752
Rutin .................................................................................................................................................... 3753

S
Sachar而成 ........................................................................................................................................ 3759
Sachararin sodium ............................................................................................................................. 3760
Saccharin sodium ............................................................................................................................... 3760
Safed, viral (5.1.7) ............................................................................................................................... 637
Safflower flower ............................................................................................................................... 1606
Safflower oil, refined ........................................................................................................................ 3761
Safron for homoeopathic preparations ............................................................................................. 1710
Sage leaf (Salvia officinalis) ............................................................................................................ 1607
Sage leaf, three-lobed ....................................................................................................................... 1608
Sage oil, Spanish ............................................................................................................................... 1629
Sage tincture ...................................................................................................................................... 1609
Salbutamol ....................................................................................................................................... 3761
Salbutamol sulfate ............................................................................................................................ 3764
Salcyclic acid ..................................................................................................................................... 3766
Salmonella enterica serovar (inactivated) ...................................................................................... 3769
Salmonella Enteritidis vaccine (inactivated) for chickens ............................................................... 1152
Salmonella Typhimurium vaccine (inactivated) for chickens ............................................................ 1155
Salmonella Typhimurium vaccine (live, oral) for chickens .............................................................. 1156
Salmonids, infectious pancreatic necrosis vaccine (inactivated oil-adjuvant, injectable) .................................................. 1124
Salvia miltiorrhiza root and rhizome ............................................................................................. 1610
Sanguisorba root ............................................................................................................................... 1611
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Saponification value (2.5.6) .............................................................................................................. 169
Sterility, guidelines for using the test for (5.1.9).............. 639
Sterols in fatty oils (2.4.23.).............................................. 150
Sticks .................................................................................. 937
Sticks, intracutaneous......................................................... 920
Sticks, nasal ......................................................................... 920
Stomata and stomatal index (2.8.3.)................................. 305
Stramonium leaf .................................................................. 1638
Stramonium, prepared .......................................................... 1640
Strands, sterile non-absorbable, in distributor for veterinary use .......................................................... 1283
Streptomycin concentrated solution .................................. 2301
Streptomycin sulfate .............................................................. 3902
Strontium (90Sr) chloride injection ...................................... 1242
Strychnos ignatii for homeopathic preparations ................. 1719
Subdivision of tablets ........................................................... 937
Sublingual sprays, oromucosal drops and oromucosal sprays ........................................................................ 920
Sublingual tablets and buccal tablets .................................. 922
Substances for pharmaceutical use, control of impurities in
(5.10.) ....................................................................................... 763
Substitution of in vivo method(s) by in vitro method(s) for the quality control of vaccines (5.2.14) ......................... 679
Sub-visible particles, particulate contamination (2.9.19.) .. 360
Sucralose ............................................................................. 3905
Sucrose ................................................................................ 3906
Sucrose, liquid ..................................................................... 3908
Sucrose monopalmitate ......................................................... 3909
Sucrose stearate .................................................................. 3911
Sufentanil ............................................................................. 3912
Sufentanil citrate .................................................................. 3913
Sugar spheres ..................................................................... 3915
Sugars, lead in (2.4.10.) ........................................................ 142
Sultamicillin tosilate dihydrate ............................................. 3944
Sulfadimidine ................................................................. 3920
Sulfadoxine ........................................................................ 3921
Sulfadiazine ........................................................................ 3922
Sulfacetamide sodium .......................................................... 3924
Sulfafurazole ...................................................................... 3925
Sulfaguanidine .................................................................... 3926
Sulfamerazine ...................................................................... 3926
Sulfamethizole .................................................................... 10.1-4949
Sulfamethoxazole ................................................................. 3928
Sulfamidazine for veterinary use ........................................ 1442
Sulfanilamide ....................................................................... 3930
Sulfasalazine ........................................................................ 3931
Sulfated ash (2.4.14) ............................................................ 142
Sulfates (2.4.13) ................................................................ 142
Sulfathiazole ......................................................................... 3933
Sulfapyridine ....................................................................... 3934
Sulfobutylbetadex sodium ................................................... 3935
Sulfadoxine ........................................................................ 3935
Sulfur dioxide (2.5.29.) ........................................................ 177
Sulfur for external use ............................................................ 3938
Sulfur for homoeopathic preparations ................................ 1727
Sulfuric acid .......................................................................... 3938
Sulindac ................................................................................ 3939
Sulpiride .............................................................................. 3940
Sulmamic acid ..................................................................... 3941
Sultamicillin tosilate dihydrate ............................................. 3944
Sumatriptan succinate .......................................................... 3946
Sunflower oil, refined ........................................................... 3948
Supercritical fluid chromatography (2.2.45.) ....................... 80
Suppositories ......................................................................... 934
Suppositories, and pessaries, disintegration of (2.9.1) ......... 325
Suppositories, lipophilic, softening time determination
(2.9.22.) .................................................................................. 363
Suspensions, solutions and emulsions, oral ......................... 917
Suspensions, solutions, intrathecal ...................................... 914
Sutures for human use: introduction .................................. 10.1-4349
Sutures, sterile non-absorbable ........................................... 1270
Sutures, sterile synthetic absorbable braided ......................... 9274
Sutures, sterile synthetic absorbable monofilament .......... 1275
Suxamethonium chloride ..................................................... 3948
Suxibuzone ........................................................................... 3949
Sweet fennel ........................................................................ 1434
Sweet orange oil .................................................................. 1641
Swelling index (2.8.4.) .......................................................... 306
Swine erysipelas vaccine (inactivated) ................................ 1158
Swine-fever vaccine (live, prepared in cell cultures),
classical .................................................................................. 10.2-4667
Symbols and abbreviations (1.) ......................................... 3
Synthetic absorbable braided sutures, sterile ......................... 1274
Synthetic absorbable monofilament sutures, sterile ............ 1275
Syringes, plastic, sterile single-use (3.3.8.) ......................... 477
Syrups ................................................................................... 918
Szechwan lovage rhizome .................................................... 1642
T
Table of physical characteristics of radionuclides mentioned in the European Pharmacopoeia (5.7.) ........................................ 745
Tablets .................................................................................. 937
Tablets and capsules, disintegration of (2.9.1) ....................... 323
Tablets and powders for rectal solutions and suspensions .... 934
Tablets, buccal ..................................................................... 922
Tablets, chewable .................................................................. 939
Tablets, coated ................................................................. 938
Tablets, dispersible ............................................................. 938
Tablets, effervescent ............................................................ 939
Tablets for intrauterine solutions and suspensions ............ 914
Tablets for vaginal solutions and suspensions ................... 941
Tablets, gastro-resistant ....................................................... 938
Tablets, intrauterine .............................................................. 914
Tablets, modified-release .................................................... 939
Tablets, orodispersible ........................................................ 939
Tablets, resistance to crushing (2.9.8.) .............................. 337
Tablets, soluble .................................................................... 939
Tablets, subdivision of ......................................................... 937
Tablets, sublingual ............................................................... 922
Tablets, uncoated ................................................................. 938
Tablets, uncoated, friability of (2.9.7.) ................................. 336
Tablets, vaginal ................................................................. 10.1-491
Talcalcitrol monohydrate .................................................... 3953
Tacrolimus monohydrate ...................................................... 3954
Tadalafil .............................................................................. 3957
Talc ......................................................................................... 3957
Talunefen citrate .................................................................... 3961
Tampons, ear ....................................................................... 998
Tampons, medicated ............................................................ 940
Tampons, rectal ................................................................. 940
Tampons, vaginal, medicated ............................................... 941
Tamsulosin hydrochloride .................................................... 3963
Tannic acid ........................................................................... 3964
Tannins in herbal drugs (2.8.14) ........................................... 310
Tapentadol hydrochloride .................................................... 3965
Tapentadol hydrochloride .................................................... 3965
Tartaric acid ........................................................................ 3966
Tea tree oil ........................................................................... 1643
Teat dips ............................................................................... 942
Teat sprays .......................................................................... 942
Technetium (99mTc) bicisate injection .................................. 1243
Technetium (99mTc) colloidal rhenium sulphide injection .... 1244
Technetium (99mTc) colloidal sulfur injection ...................... 1244
Technetium (99mTc) colloidal tin injection ......................... 1245
Technetium (99mTc) etiopin injection .................................. 1246
Technetium (99mTc) exametazime injection ......................... 1247
Technetium (99mTc) glucenate injection ............................. 1248
Technetium (99mTc) human albumin injection ..................... 1249
Technetium (99mTc) sodium iodate injection ...................... 1250
Technetium (99mTc) mebrofenin injection .......................... 10.1-4345
Technetium (99mTc) medronate injection ......................... 1253
<table>
<thead>
<tr>
<th>Index</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tizanidine hydrochloride</td>
<td>4053</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>4055</td>
</tr>
<tr>
<td>Tocopherol, all-rac-α</td>
<td>4057</td>
</tr>
<tr>
<td>Tocopherol, all-rac-α, powder</td>
<td>4058</td>
</tr>
<tr>
<td>Tocopheryl acetate, all-rac-α</td>
<td>4059</td>
</tr>
<tr>
<td>α-Tocopheryl acetate concentrate (powder)</td>
<td>4062</td>
</tr>
<tr>
<td>Tocopheryl acetate, RRR-α</td>
<td>4060</td>
</tr>
<tr>
<td>Tocopheryl hydrogen succinate, DL-α</td>
<td>4062</td>
</tr>
<tr>
<td>Tocopheryl hydrogen succinate, RRR-α</td>
<td>4064</td>
</tr>
<tr>
<td>Tolbutamide</td>
<td>4066</td>
</tr>
<tr>
<td>Tolenuic acid</td>
<td>4067</td>
</tr>
<tr>
<td>Tolnaftate</td>
<td>4068</td>
</tr>
<tr>
<td>Tolterodine tartrate</td>
<td>4070</td>
</tr>
<tr>
<td>Toluidine</td>
<td>1649</td>
</tr>
<tr>
<td>Toluenesulfonate (methyl, ethyl and isopropyl) in active substances</td>
<td>185</td>
</tr>
<tr>
<td>Topiramate</td>
<td>4071</td>
</tr>
<tr>
<td>Torsamide</td>
<td>4073</td>
</tr>
<tr>
<td>Toremtin tincture</td>
<td>1650</td>
</tr>
<tr>
<td>Tosylchloramide sodium</td>
<td>4074</td>
</tr>
<tr>
<td>Total ash (2.4.16.)</td>
<td>143</td>
</tr>
<tr>
<td>Total cholesterol in oils rich in omega-3 acids (2.4.32.)</td>
<td>163</td>
</tr>
<tr>
<td>Total organic carbon in water for pharmaceutical use (2.5.4)</td>
<td>79</td>
</tr>
<tr>
<td>Total protein (5.2.33.)</td>
<td>178</td>
</tr>
<tr>
<td>Traditional Chinese medicine, names of herbal drugs used in (5.2.2)</td>
<td>4101-4335</td>
</tr>
<tr>
<td>Tragacanth</td>
<td>1651</td>
</tr>
<tr>
<td>Tramadol hydrochloride</td>
<td>4074</td>
</tr>
<tr>
<td>Tramazoline hydrochloride monohydrate</td>
<td>4076</td>
</tr>
<tr>
<td>Tranodapril</td>
<td>4077</td>
</tr>
<tr>
<td>Tranexamic acid</td>
<td>10.1-4504</td>
</tr>
<tr>
<td>Transdermal patches</td>
<td>925</td>
</tr>
<tr>
<td>Transdermal patches, dissolution test for (2.9.4.)</td>
<td>333</td>
</tr>
<tr>
<td>Trapidil</td>
<td>4079</td>
</tr>
<tr>
<td>Trehalose dihydrate</td>
<td>4080</td>
</tr>
<tr>
<td>Tretinoin</td>
<td>4082</td>
</tr>
<tr>
<td>Triacetin</td>
<td>4083</td>
</tr>
<tr>
<td>Triacynolone</td>
<td>4083</td>
</tr>
<tr>
<td>Triamcinolone acetone</td>
<td>4085</td>
</tr>
<tr>
<td>Triamcinolone hexacetonide</td>
<td>4086</td>
</tr>
<tr>
<td>Triamterene</td>
<td>4088</td>
</tr>
<tr>
<td>Tribenoside</td>
<td>4089</td>
</tr>
<tr>
<td>Tributyl acetate</td>
<td>4090</td>
</tr>
<tr>
<td>Trichloroacetic acid</td>
<td>4092</td>
</tr>
<tr>
<td>Trichloroethylene for veterinary use</td>
<td>4093</td>
</tr>
<tr>
<td>Triethanolamines</td>
<td>4097</td>
</tr>
<tr>
<td>Triethyl citrate</td>
<td>4094</td>
</tr>
<tr>
<td>Trifluoperazine hydrochloride</td>
<td>4095</td>
</tr>
<tr>
<td>Trifluralin</td>
<td>4095</td>
</tr>
<tr>
<td>Triglycerides, medium-chain</td>
<td>4096</td>
</tr>
<tr>
<td>Triglycerides, omega-3-acid</td>
<td>3423</td>
</tr>
<tr>
<td>Triglycol diisostearate</td>
<td>4097</td>
</tr>
<tr>
<td>Trihexyphenyl hydrochloride</td>
<td>4098</td>
</tr>
<tr>
<td>Trimethobenzene</td>
<td>4099</td>
</tr>
<tr>
<td>Trimeprazine hemitartrate</td>
<td>1782</td>
</tr>
<tr>
<td>Trimeprazine dihydrochloride</td>
<td>4100</td>
</tr>
<tr>
<td>Trimethadione</td>
<td>4101</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>4102</td>
</tr>
<tr>
<td>Trimipramine maleate</td>
<td>4104</td>
</tr>
<tr>
<td>Tri-n-butyl phosphate</td>
<td>4091</td>
</tr>
<tr>
<td>Tritiated (^1H) water injection</td>
<td>1263</td>
</tr>
<tr>
<td>Trolamine</td>
<td>4106</td>
</tr>
<tr>
<td>Trometamol</td>
<td>4107</td>
</tr>
<tr>
<td>Tropicamid</td>
<td>4108</td>
</tr>
<tr>
<td>Tropisetron hydrochloride</td>
<td>4110</td>
</tr>
<tr>
<td>Tropium chloride</td>
<td>4111</td>
</tr>
<tr>
<td>Troperutin</td>
<td>4112</td>
</tr>
<tr>
<td>Trypsin</td>
<td>4114</td>
</tr>
<tr>
<td>Tryptophan</td>
<td>4115</td>
</tr>
<tr>
<td>TSE, animal, minimising the risk of transmitting via human and veterinary medicinal products (5.2.8.)</td>
<td>661</td>
</tr>
<tr>
<td>TSE, animal, products with risk of transmitting agents of...</td>
<td>884</td>
</tr>
<tr>
<td>Tuberculin for human use</td>
<td>4117</td>
</tr>
<tr>
<td>Tuberculin purified protein derivative, avian</td>
<td>4119</td>
</tr>
<tr>
<td>Tuberculin purified protein derivative, bovine</td>
<td>4120</td>
</tr>
<tr>
<td>Tuberculin purified protein derivative for human use</td>
<td>4120</td>
</tr>
<tr>
<td>Tuberculosis (BCG) vaccine, freeze-dried</td>
<td>949</td>
</tr>
<tr>
<td>Tubes for comparative tests (2.1.5.)</td>
<td>17</td>
</tr>
<tr>
<td>Tubing and closures, silicone elastomer for (3.1.9.)</td>
<td>436</td>
</tr>
<tr>
<td>Tubing and containers for total parenteral nutrition</td>
<td>434</td>
</tr>
<tr>
<td>Tubing used in sets for the transfusion of blood and blood components, materials based on plasticised poly(vinyl chloride) for (3.3.3.)</td>
<td>468</td>
</tr>
<tr>
<td>Turkey infectious rhinotracheitis vaccine (live)</td>
<td>10.2-4668</td>
</tr>
<tr>
<td>Turmeric, Javanese</td>
<td>1652</td>
</tr>
<tr>
<td>Turmeric rhizome</td>
<td>1653</td>
</tr>
<tr>
<td>Turpentine oil</td>
<td>1655</td>
</tr>
<tr>
<td>Tylosin for veterinary use</td>
<td>4122</td>
</tr>
<tr>
<td>Tylosin phosphate bulk solution for veterinary use</td>
<td>4127</td>
</tr>
<tr>
<td>Tylosin phosphate for veterinary use</td>
<td>4131</td>
</tr>
<tr>
<td>Tyloxitartri dent for veterinary use</td>
<td>4136</td>
</tr>
<tr>
<td>Typhae pollen</td>
<td>1656</td>
</tr>
<tr>
<td>Typhoid polysaccharide and hepatitis A (inactivated, adsorbed) vaccine</td>
<td>982</td>
</tr>
<tr>
<td>Typhoid polysaccharide vaccine</td>
<td>1044</td>
</tr>
<tr>
<td>Typhoid vaccine</td>
<td>1046</td>
</tr>
<tr>
<td>Typhoid vaccine (live, oral, strain Ty 21a)</td>
<td>1046</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>4140</td>
</tr>
<tr>
<td>Tyrothricin</td>
<td>4142</td>
</tr>
</tbody>
</table>

U

<table>
<thead>
<tr>
<th>Index</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ubidecarenone</td>
<td>4147</td>
</tr>
<tr>
<td>Udder-washes</td>
<td>942</td>
</tr>
<tr>
<td>Ultraviolet and visible absorption spectrophotometry (2.2.3.)</td>
<td>42</td>
</tr>
<tr>
<td>Ultraviolet ray lamps for analytical purposes (2.1.3.)</td>
<td>15</td>
</tr>
<tr>
<td>Uncaria stem with hooks</td>
<td>1657</td>
</tr>
<tr>
<td>Uncoated tablets</td>
<td>938</td>
</tr>
<tr>
<td>Undecylenic acid</td>
<td>4148</td>
</tr>
<tr>
<td>Uniformity of content of single-dose preparations (2.9.6.)</td>
<td>336</td>
</tr>
<tr>
<td>Uniformity of dosage units (2.9.40.)</td>
<td>398</td>
</tr>
<tr>
<td>Uniformity of dosage units, demonstration using large sample sizes</td>
<td>409</td>
</tr>
<tr>
<td>Uniformity of mass of delivered doses from multidose containers</td>
<td>372</td>
</tr>
<tr>
<td>Uniformity of mass of single-dose preparations (2.9.5.)</td>
<td>335</td>
</tr>
<tr>
<td>Units of the International System (SI) used in the Pharmacopoeia and equivalence with other units (1.)</td>
<td>3</td>
</tr>
<tr>
<td>Unsoapifiable matter (2.5.7.)</td>
<td>169</td>
</tr>
<tr>
<td>Urea</td>
<td>4149</td>
</tr>
<tr>
<td>Urofolitropin</td>
<td>4149</td>
</tr>
<tr>
<td>Urokinase</td>
<td>4151</td>
</tr>
<tr>
<td>Uronic acids in polysaccharide vaccines (2.5.22.)</td>
<td>174</td>
</tr>
<tr>
<td>Urosoxycholic acid</td>
<td>4152</td>
</tr>
<tr>
<td>Utica dioica for homoeopathic preparations</td>
<td>1728</td>
</tr>
</tbody>
</table>

V

<table>
<thead>
<tr>
<th>Index</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine component assay by immunonephelometry (2.7.35.)</td>
<td>301</td>
</tr>
<tr>
<td>Vaccines, adsorbed, aluminium in (2.5.13.)</td>
<td>171</td>
</tr>
<tr>
<td>Vaccines, adsorbed, calcium in (2.5.14.)</td>
<td>172</td>
</tr>
<tr>
<td>Vaccines and immunosera, phenol in (2.5.15.)</td>
<td>172</td>
</tr>
<tr>
<td>Vaccines and immunosera, veterinary, evaluation of efficacy (5.2.7.)</td>
<td>661</td>
</tr>
<tr>
<td>Vaccines and immunosera, veterinary, evaluation of safety (5.2.6.)</td>
<td>658</td>
</tr>
<tr>
<td>Vaccines for human use</td>
<td>893</td>
</tr>
<tr>
<td>Vaccines for human use, cell substrates for the production of (5.2.3.)</td>
<td>650</td>
</tr>
<tr>
<td>Vaccines for human use, conjugated polysaccharide, carrier proteins for the production of (5.2.11.)</td>
<td>674</td>
</tr>
</tbody>
</table>

See the information section on general monographs (cover pages)
Index

Vaccines for human use, viral, tests for extraneous agents in (5.2.16.3) ................................................. 10.2-4579
Vaccines for veterinary use ......................................................................................................................... 10.2-4604
Vaccines, substitution of in vivo method(s) by in vitro method(s) for the quality control of (5.2.2.1) .................................................................................................................. 679
Vaccines, veterinary, cell cultures for the production of (5.2.4.1) .............................................................. 10.2-4589
Vaccines, viral live, test for neurovirulence (2.6.18.) ..................................................................................... 218
Vaginal capsules ............................................................................................................................................ 941
Vaginal foams .................................................................................................................................................. 941
Vaginal preparations ....................................................................................................................................... 940
Vaginal preparations, semi-solid ................................................................................................................... 941
Vaginal solutions, emulsions and suspensions ............................................................................................. 941
Vaginal tablets ................................................................................................................................................ 941
Vaginal tampons, medicated .......................................................................................................................... 939
Valaciclovir hydrochloride ............................................................................................................................. 4157
Valaciclovir hydrochloride hydrate .............................................................................................................. 4160
Valerian dry aqueous extract ........................................................................................................................ 1659
Valerian dry alcoholic extract ....................................................................................................................... 1660
Valerian root .................................................................................................................................................. 1660
Valerian root, cut ............................................................................................................................................ 1662
Valerian tincture ............................................................................................................................................ 1664
Validation of nucleic acid amplification techniques for the detection of B19 virus (B19V) DNA in plasma pools: guidelines ........................................................................................................................................ 219
Valine ............................................................................................................................................................. 4162
Valenulin hydrochloride for veterinary use ................................................................................................. 4164
Valproate, sodium ......................................................................................................................................... 3849
Valproic acid .................................................................................................................................................. 4165
Valstarin ......................................................................................................................................................... 4167
Vancomycin hydrochloride ........................................................................................................................... 4168
Vanillin ........................................................................................................................................................... 4172
Vapour, preparations to be converted into .................................................................................................... 928
Vardenafil hydrochloride trihydrate ............................................................................................................ 4172
Varicella immunoglobulin for intravenous administration, human ................................................................ 2875
Varicella immunoglobulin, human nucleic acid amplification techniques for the detection of hepatitis C virus (HCV) RNA in plasma pools: guidelines ........................................................................................................ 219
Varicella, measles, mumps and rubella vaccine (live) .................................................................................. 1006
Varicella vaccine (live) .................................................................................................................................. 1048
Vectors for human use, adeno-associated-virus .......................................................................................... 788
Vectors for human use, adenovirus ............................................................................................................ 782
Vectors for human use, plasmid ................................................................................................................. 780
Vectors for human use, plasmid, bacterial cells used for the manufacture of ............................................ 781
Vectors for human use, poxvirus ................................................................................................................ 784
Vectors for human use, retrovirdiae-derived ............................................................................................... 786
Vercunronium bromide ................................................................................................................................... 4173
Vedaprofen for veterinary use ....................................................................................................................... 4175
Vegetable fatty oils ......................................................................................................................................... 901
Venlafaxine hydrochloride ............................................................................................................................. 4176
Verapamil hydrochloride .................................................................................................................................. 4179
Verbenone herb ................................................................................................................................................ 1761
Veterinary liquid preparations for cutaneous application ........................................................................... 941
Veterinary medicinal products, immunological, management of extraneous agents in (5.2.5.3) ............ 10.2-4590
Veterinary semi-solid preparations for oral use .......................................................................................... 942

Veterinary vaccines and immunosera, evaluation of efficacy of (5.2.7.1) .................................................. 661
Viability, nucleated cell count and (2.7.29.) ................................................................................................. 297
Vibriosis (cold-water, inactive) .................................................................................................................. 10.2-4592
Vibriosis vaccine (inactivated) for salmonids ............................................................................................. 1163
Vibriosis vaccine (inactivated) for salmonids ............................................................................................. 1164
VICH (5.8.) ..................................................................................................................................................... 755
Vigabatrin ....................................................................................................................................................... 4180
Vinblastine sulfate ......................................................................................................................................... 4181
Vincamine ....................................................................................................................................................... 4182
Vindesine sulfate .......................................................................................................................................... 4183
Viren Delhi tarter ........................................................................................................................................... 4186
Vinpocetine ..................................................................................................................................................... 4188
Viper venom antiserum, European ............................................................................................................. 1174
Viral diarrhoea vaccine (inactivated), bovine ............................................................................................ 1075
Viral hepatitis type I vaccine (live), duck .................................................................................................... 10.2-4647
Viral rhinotracheitis vaccine (inactivated), feline ...................................................................................... 1113
Viral rhinotracheitis vaccine (live), feline ................................................................................................. 10.2-4652
Viral safety (5.1.7.) ....................................................................................................................................... 637
Viral tonsenovistis vaccine (live), avian ....................................................................................................... 10.2-4632
Viral vaccines for human use, tests for extraneous agents in (2.6.16.3) ....................................................... 10.2-4579
Viscometer method, capillary (2.2.9.) ........................................................................................................... 27
Viscometer methods, falling ball and automatic rolling ball .................................................................. 94
Viscose wadding, absorbent ....................................................................................................................... 4189
Viscosity - rotating viscometer method (2.2.10.) .......................................................................................... 28
Viscosity (2.2.8.) .......................................................................................................................................... 27
Visible and ultraviolet absorption spectrophotometry (2.2.23.) .................................................................. 42
Visible particles, particulate contamination (2.9.20.) ................................................................................. 362
Vitamin A....................................................................................................................................................... 4191
Vitamin A concentrate (oily form), synthetic ............................................................................................. 4192
Vitamin A concentrate (powder form), synthetic ....................................................................................... 4193
Vitamin A concentrate (solubilisate/emulsion), synthetic ......................................................................... 4194
Volumetric titration (2.2.65.) ....................................................................................................................... 119
Volumetric analysis (4.2.) ........................................................................................................................... 609
Volumetric solutions, primary standards for (4.2.1.1) .............................................................................. 609
Volumetric solutions, primary standards for (4.2.1.1) ............................................................................. 10.1-4331
von Willebrand factor, human ................................................................................................................... 2875
von Willebrand factor, human, assay of (2.7.21.) ..................................................................................... 290
Voriconazole ................................................................................................................................................ 4196
W
Warfarin sodium ......................................................................................................................................... 4201
Warfarin sodium clathrate ............................................................................................................................ 4202
Washes, nasal .................................................................................................................................................. 920
Water ("O") injection ..................................................................................................................................... 1264
Water activity and sorption-desorption isotherms, determination of (water-solid interactions) (2.9.39.) .... 394
Water, determination by distillation (2.2.13.) ............................................................................................ 31
Water for diluting concentrated haemodialysis solutions ........................................................................... 2797
Water for injections ....................................................................................................................................... 4203
Water for pharmaceutical use, total organic carbon in (2.2.44.) ................................................................ 79
Water for preparation of extracts .............................................................................................................. 4206
Water in essential oils (2.8.5.) ..................................................................................................................... 306
Water in gases (2.5.28.) ............................................................................................................................. 176
Water: micro determination (2.5.32.) ........................................................................................................ 178
Water, purified ............................................................................................................................................... 4207
Water: semi-micro determination (2.5.12.) ............................................................................................... 171
Water-solid interactions: determination of sorption-desorption isotherms and of water activity (2.9.39.) ... 394
Wettability of porous solids including powders (2.9.43.) ................................................................. 406
Wheat starch ................................................................................................................................................. 4209
Wheat-germ oil, refined .............................................................................................................................. 4170
Wheat-germ oil, virgin ................................................................................................................................. 4210
White beeswax ............................................................................................................................................. 1931

General Notices (1) apply to all monographs and other texts

4727
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>White horehound .................................................</td>
</tr>
<tr>
<td>White peony root ................................................</td>
</tr>
<tr>
<td>White soft paraffin .............................................</td>
</tr>
<tr>
<td>Wild pansy (flowering aerial parts) ........................</td>
</tr>
<tr>
<td>Wild thyme .........................................................</td>
</tr>
<tr>
<td>Willow bark ..........................................................</td>
</tr>
<tr>
<td>Willow bark dry extract ....................................</td>
</tr>
<tr>
<td>Wool alcohols ..........................................................</td>
</tr>
<tr>
<td>Wool fat .................................................................</td>
</tr>
<tr>
<td>Wool fat, hydrogenated ...........................................</td>
</tr>
<tr>
<td>Wool fat, hydrours ................................................</td>
</tr>
<tr>
<td>Wormwood ...............................................................</td>
</tr>
<tr>
<td>Xanthan gum ............................................................</td>
</tr>
<tr>
<td>Xenon (¹³⁷Xe) injection ...........................................</td>
</tr>
<tr>
<td>X-ray fluorescence spectrometry (2.2.37.) ................</td>
</tr>
<tr>
<td>X-ray powder diffraction (XRPD), characterisation of crystalline and partially crystalline solids by (2.9.33.)</td>
</tr>
<tr>
<td>Xylazine hydrochloride for veterinary use ..................</td>
</tr>
<tr>
<td>Xylitol .................................................................</td>
</tr>
<tr>
<td>Xylometazoline hydrochloride ..................................</td>
</tr>
<tr>
<td>Xylose .................................................................</td>
</tr>
<tr>
<td>Yarrow ..................................................................</td>
</tr>
<tr>
<td>Yeasticidal, bactericidal or fungicidal activity of antiseptic medicinal products, determination of (5.1.11.)</td>
</tr>
<tr>
<td>Yellow beeswax ..........................................................</td>
</tr>
<tr>
<td>Yellow fever vaccine (live) ....................................</td>
</tr>
<tr>
<td>Yellow soft paraffin ..............................................</td>
</tr>
<tr>
<td>Yersiniosis vaccine (inactivated) for salmonids ........</td>
</tr>
<tr>
<td>Yohimbine hydrochloride .........................................</td>
</tr>
<tr>
<td>Yttrium (¹⁹⁸Y) chloride solution for radiolabelling ..........</td>
</tr>
<tr>
<td>Zanamivir hydrate ..................................................</td>
</tr>
<tr>
<td>Zanthoxylum bungeanum pericarp ................................</td>
</tr>
<tr>
<td>Zidovudine .............................................................</td>
</tr>
<tr>
<td>Zinc acetate dihydrate ..........................................</td>
</tr>
<tr>
<td>Zinc acexamate ........................................................</td>
</tr>
<tr>
<td>Zinc chloride ...........................................................</td>
</tr>
<tr>
<td>Zinc gluconate .......................................................</td>
</tr>
<tr>
<td>Zinc oxide .............................................................</td>
</tr>
<tr>
<td>Zinc stearate ...........................................................</td>
</tr>
<tr>
<td>Zinc sulfate heptahydrate .......................................</td>
</tr>
<tr>
<td>Zinc sulfate hexahydrate .........................................</td>
</tr>
<tr>
<td>Zinc sulfate monohydrate .........................................</td>
</tr>
<tr>
<td>Zinc undecylenate ..................................................</td>
</tr>
<tr>
<td>Ziprasidone mesilate trihydrate ..................................</td>
</tr>
<tr>
<td>Zoledronic acid monohydrate ....................................</td>
</tr>
<tr>
<td>Zolmitriptan ............................................................</td>
</tr>
<tr>
<td>Zolpidem tartrate ...................................................</td>
</tr>
<tr>
<td>Zopiclone ..............................................................</td>
</tr>
<tr>
<td>Zoster (shingles) vaccine (live), herpes .....................</td>
</tr>
<tr>
<td>Zuclopenthixol decanoate ........................................</td>
</tr>
</tbody>
</table>